deaths (OS)

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC) 2 certainty unassessablestatistically conclusive-27%